MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) is confident its CimetrA treatment has wide-ranging applications.
As such the company is now advancing the treatment which was originally designed to evaluate the efficacy and safety of a treatment for COVID-19.
Chief medical officer Nadya Lisovoder tells Proactive that a recent pre-clinical trial has opened up new opportunities for the treatment, and the next steps may include a focus on rheumatoid arthritis “because of the huge market size and unmet needs.”